Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.68) by 8.82 percent. This is a 23.33 percent decrease over losses of $(0.60) per share from the same period last year.